1. Home
  2. NXGL vs SNOA Comparison

NXGL vs SNOA Comparison

Compare NXGL & SNOA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo NexGel Inc

NXGL

NexGel Inc

HOLD

Current Price

$0.42

Market Cap

4.9M

Sector

Health Care

ML Signal

HOLD

Logo Sonoma Pharmaceuticals Inc.

SNOA

Sonoma Pharmaceuticals Inc.

HOLD

Current Price

$1.18

Market Cap

5.8M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
NXGL
SNOA
Founded
1997
1999
Country
United States
United States
Employees
19
N/A
Industry
Medical/Dental Instruments
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
4.9M
5.8M
IPO Year
N/A
2006

Fundamental Metrics

Financial Performance
Metric
NXGL
SNOA
Price
$0.42
$1.18
Analyst Decision
Strong Buy
Analyst Count
1
0
Target Price
$2.00
N/A
AVG Volume (30 Days)
330.7K
90.9K
Earning Date
05-11-2026
06-16-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
32.26
EPS
N/A
N/A
Revenue
N/A
$19,529,000.00
Revenue This Year
$50.77
$23.00
Revenue Next Year
$46.15
$24.59
P/E Ratio
N/A
N/A
Revenue Growth
N/A
36.68
52 Week Low
$0.41
$0.85
52 Week High
$2.89
$6.92

Technical Indicators

Market Signals
Indicator
NXGL
SNOA
Relative Strength Index (RSI) N/A N/A
Support Level N/A N/A
Resistance Level N/A N/A
Average True Range (ATR) 0.00 0.00
MACD 0.00 0.00
Stochastic Oscillator 0.00 0.00

Price Performance

Historical Comparison
NXGL
SNOA

About NXGL NexGel Inc

NexGel Inc manufactures high water content, electron beam cross-linked, aqueous polymer hydrogels, or gels, used for wound care, medical diagnostics, transdermal drug delivery, and cosmetics. The company specializes in custom gels by capitalizing on proprietary manufacturing technologies. The gels and consumer products are manufactured using proprietary and non-proprietary mixing, coating and cross-linking technologies.

About SNOA Sonoma Pharmaceuticals Inc.

Sonoma Pharmaceuticals Inc is a specialty pharmaceutical company operating in the United States. It is engaged in identifying, developing, and commercializing differentiated therapies for patients living with chronic skin conditions. The company focuses on the development and commercialization of therapeutic solutions in medical dermatology to treat skin conditions, such as acne, atopic dermatitis, and scarring. The key products of the company are Celacyn, Ceramax Skin Barrier Cream, Mondoxyne, Alevicyn, SebuDerm, Microcyn, and Microcyn which are available for various skin treatments such as scars, itchy skin, minor skin irritations, rashes, and others. The company derives revenue from the sale of products in the United States, Latin America, Europe, Asia, and other countries.

Share on Social Networks: